Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.USFDA accepts NextPoint Therapeutics’s IND for NPX887
NextPoint Therapeutics intends to begin a first-in-human Phase I clinical trial in early 2024 analysing NPX887 in patients with solid tumours. Credit: fernando zhiminaicela from Pixabay.
NextPoint Therapeutics intends to begin a first-in-human Phase I clinical trial in early 2024 analysing NPX887 in patients with solid tumours. Credit: fernando zhiminaicela from Pixabay.